GILEAD SCIENCES BELGIUM
ActiveDirectors
Directors
5 directors, 2 in day-to-day management, no change since 2025
Board 5
Hans York-Julian Stücker
Current
Director · since 01-02-2023 · term without a fixed end · listed in the 2025 annual accounts, filed on 26-05-2026
Sabine Tews
Current
Director · since 01-07-2024 · term without a fixed end · listed in the 2025 annual accounts, filed on 26-05-2026
Josephine Yang Comiskey
Current
Director · since 31-10-2024 · term without a fixed end · listed in the 2025 annual accounts, filed on 26-05-2026
Luís Eduardo Viana De Oliveira Martins
Current
Director · current term since 31-10-2024 · term without a fixed end · listed in the 2025 annual accounts, filed on 26-05-2026
J.Peche Marín-Lázaro
Current
Director · since 31-01-2025 · term without a fixed end · listed in the 2025 annual accounts, filed on 26-05-2026
Day-to-day management 2
Sabine Tews
Current
Managing director · appointed by deed of 25-07-2024 · term without a fixed end
Luís Eduardo Viana De Oliveira Martins
Current
Managing director · appointed by deed of 20-02-2025 · term without a fixed end
Statutory auditor 1
Ernst et Young Reviseurs d'Entreprises
Current
Statutory auditor · current term since 10-05-2024 · 3-year term from 2024 · permanent representative: Eef NAESSENS · listed in the 2025 annual accounts, filed on 26-05-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Two directors jointly
deed of 25-07-2024Owners and capital
Shareholders
2 ownersChain of control
- Gilead Sciences Inc.US
- GILEAD SCIENCES BELGIUM
Owners 2
- Gilead Sciences Ireland UCIEparentSourceown accounts 2025100%
- Gilead Sciences Inc.USconsolidating parentconsolidates
Owners through the years 2006 to 2025
| Name | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Ireland UCIE | consolidates | listed | 100% | |||||||||||||||||
| Gilead Sciences Inc.US | consolidates | |||||||||||||||||||
| Gilead Sciences Europe LtdGB | listed | |||||||||||||||||||
| Gilead Sciences LimitedIE | consolidates | |||||||||||||||||||
Source: shareholder structure in its own accounts, parent in its own accounts
Capital transactions
Shareholders according to the deeds
Stated in the deed
deed of 24-10-2022 ↗
- één persoon all shares
Capital over time
- 23-07-2024 Capital stated in 2 deeds · 343,550 shares
- 26-05-2008 Capital increase of €300,000 · to €343,550 · 300,000 new shares, 87.3% of the 343,550 shares after the increase
Mandate history
30 people, 6 in office
- Board
- Day-to-day management
- Permanent representative
- Statutory auditor
- mandate already running before its first mention
- end not dated
| Name | Functions and periods |
|---|---|
| Luís Eduardo Viana De Oliveira Martins |
|
| Hans York-Julian Stücker |
|
| Sabine Tews |
|
| Josephine Yang Comiskey |
|
| J.Peche Marín-Lázaro |
|
| Ernst et Young Reviseurs d'Entreprises |
|
| John Andrew Jorden |
|
| Marc Esque Ingles |
|
| Janet Elizabeth Dorling |
|
| Willem Jozef Eeraerts |
|
| Andrew Dickinson |
|
| Brett Pletcher |
|
| Luis Miranda Rubi |
|
| Rudolf Ertl |
|
| Luis VIANA DE OLIVEIRA MARTINS |
|
| Andrew D. Dickinson |
|
| Robin Washington |
|
| Jamie Gainsborough Waring |
|
| Nicolas Walter Gouwy |
|
| Marnix Van Dooren |
|
| Ernst & Young Bedrijfsrevisoren BC CVBA |
|
| Douwe Broer Roosjen |
|
| Gregg Alton |
|
| Jaap Koelman |
|
| Rudi Ertl |
|
| Rudi Erti |
|
| Paul Carter |
|
| John Milligan |
|
| Simon Bedson |
|
| Colin Badenhorst |
|